To define the mechanism(s) responsible for the negative inotropic effects of tumor necrosis factor-a (TNFa) in the adult heart, we examined the functional effects of TNFa in the intact left ventricle and the isolated adult cardiac myocyte. Studies in both the ventricle and the isolated adult cardiac myocyte showed that TNFa exerted a concentration-and time-dependent negative inotropic effect that was fully reversible upon removal of this cytokine. Further, treatment with a neutralizing anti-TNFa antibody prevented the negative inotropic effects of TNFa in isolated myocytes. A cellular basis for the above findings was provided by studies which showed that treatment with TNFa resulted in decreased levels of peak intracellular calcium during the systolic contraction sequence; moreover, these findings did not appear to be secondary to alterations in the electrophysiological properties of the cardiac myocyte. Further studies showed that increased levels of nitric oxide, de novo protein synthesis, and metabolites of the arachidonic acid pathway were unlikely to be responsible for the TNFa-induced abnormalities in contractile function. Thus, these studies constitute the initial demonstration that the negative inotropic effects of TNFa are the direct result of alterations in intracellular calcium homeostasis in the adult cardiac myocyte. (J. Clin. Invest.
Introduction
An increasing body of experimental and clinical evidence now suggests that certain pro-inflammatory cytokines play an important role in a variety of cardiac pathophysiological conditions. TNFa is a pro-inflammatory cytokine that was originally discovered as a protein with necrotizing effects in certain transplantable mouse tumors (1) . More recently, however, this cytokine has been shown to exert a spectrum ofpleiotropic effects in different cell types. Although the major biological role for TNFa is thought to be as a host response to systemic infections, most notably gram-negative sepsis, this cytokine has also been implicated in a variety of cardiac disease states that are not considered to be attributable to bacterial infections, including acute viral myocarditis (2) , cardiac allograft rejection (3), myocardial infarction (4, 5) , and congestive heart failure (6, 7).
Previous experimental and clinical studies have suggested that there is an association between depressed myocardial function and elevated levels of TNFa (8) (9) (10) (11) (12) (13) (14) . However, the exact mechanism(s) for any potential TNFa-induced effects in the intact heart is (are) not known. Moreover given the complexity of the aforementioned pathophysiological conditions, as well as the intricate admixture of cell types in the heart, each of which may respond differently to the pleiotropic effects of TNFa, it has not been possible to determine whether TNFa has a direct effect on the cardiac myocyte itself, or whether instead this cytokine exerts its effect(s) indirectly, by releasing one or more soluble factors from nonmyocyte cell types residing within the myocardium.
The purpose of this study was to provide a focused approach toward defining the acute mechanism(s) of action of TNFa in the heart. Accordingly, in the present study we systematically examined the functional effects of TNFa in vitro both at the tissue and cellular levels. Additional studies were subsequently performed to further delineate the basic cellular and molecular mechanism(s) of action for TNFa. The results of the present study support the point of view that the negative inotropic effects of TNFa are the direct result of alterations in intracellular calcium homeostasis in the adult cardiac myocyte.
Methods

Effects of TNFa on myocardialfunction
Myocardial function was assessed using a modified Langendorffpreparation. Briefly, adult cats weighing 2.9-4.3 kg were anesthetized with ketamine hydrochloride (50 mg/kg i.m.) and acepomazine maleate (5 mg/kg i.m.), the hearts were rapidly excised and perfused at a constant rate of 35 ml/minute using a bilateral roller pump ( 15 ) . The coronary superfusate consisted of a nonrecirculating Krebs-Henseleit buffer (KHB' solution ofthe following composition (mM): NaCl 118.0, KCl 4.0, MgCI2* H20 1.2, KH2PO4 1.1, CaCl2 * 2H20 2.4, NaHCO3 25.0, glucose 5.0, L-glutamate 5.0 (pH 7.4). The solution was oxygenated with 95% 02 and 5% CO2 and maintained at 37°C by a jacketed water bath. Coronary perfusion pressure was set at 75 mmHg and remained constant throughout the course of the studies. In order to produce a closed system in which the effluent drainage from the coronary arteries and the left ventricle (LV) would not be recirculated, the pulmonary veins and vena cavae were ligated, the pulmonary artery was cannulated and the LV was drained through the left atrium. Developed LV pressure was measured by means of a fluid-filled latex balloon connected to a pressure transducer. The hearts were paced electrically at 2.2 Hz via the right atrium using a bipolar platinum electrode. All hearts were allowed to equilibrate for 30 min before the time of study.
Following the above equilibration period, a series of four separate 30-min protocols were performed. The composition of the buffer solution superfusing the heart was varied by injecting either diluent (1% The Journal of Clinical Investigation, Inc. Volume 92, November 1993, 2303-2312 BSA) or TNFa (with 1% BSA) into a side-arm port above the heart, such that the injectate mixed thoroughly with the coronary superfusate solution. The flow rate ofthe injected solution was controlled precisely by a roller-pump and remained constant at 1.8 ml/ min; the flow rate of the KHB coronary superfusate was adjusted downward accordingly, such that the total combined total flow rate ofcoronary superfusate and injectate always remained constant at 35 ml/min. Control measurements were obtained during infusion ofdiluent for 30 min; experimental measurements were obtained during infusion of 10 U/s TNFa (-17 U/ml/min) for 30 min, followed by 50 U/s TNFa (-86 U/ ml per min) for 30 min. To assess the reversibility of any TNFainduced effects, the hearts were perfused with diluent for 30 min during the final protocol.
At the start ofeach ofthe four protocols the LV balloon volume was adjusted to achieve an end-diastolic pressure of 10 mmHg, and the developed LV pressure (mmHg) and LV dP/dT(mmHg/s) recorded at intervals of 0, 5, 10, 15, 20, and 25 min. After 25 min ofcontinuous infusion, the LV balloon volume was adjusted to achieve end-diastolic pressures of 0, 5, 10, 15, and 20 mmHg: developed LV pressure was then measured for each level ofend-diastolic pressure in order to establish a LV function curve. The total duration for each experiment did not exceed 2.5 h, during which time the experimental preparation was quite stable.
Cardiocyte isolation
The morphological, meabolic, mechanical, and electrophysiological properties of the cardiocytes used in this study have been described previously (16) (17) (18) . The methods for isolating reproducible yields of calcium-tolerant cardiac myocytes have been reported previously in considerable detail (19) (20) (21) .
Cardiocyte mechanics
To determine whether TNFa had a direct effect on the contractility of the adult cardiocyte, cardiocyte motion was characterized using videoedge detection system (22) that measures changes in cell length as a function in time. To reduce the noise inherent in a single contraction sequence, the velocity of shortening was determined as the average of 10 successive beats. The change in cell length as a function oftime was then used to derive the extent and peak velocity of cell shortening.
Cardiocyte evaluation
Effects ofTNFa on cardiocyte viability. Given the well-described cytotoxic effects of TNFa on tumoral cell lines (23, 24) , we considered it important to determine whether TNFa was acutely cytotoxic to adult cardiocytes. Accordingly, freshly isolated cardiocytes were treated for 6 h with 200 U/ml of TNFa, and cardiocyte viability measured both in terms of indices of necrotic cell death and apoptotic cell death. Three indices of necrotic cell death were examined: the percentage of quiescent rod-shaped cells in 10 randomly chosen 1 x 1-mm field, the percentage of rod-shaped cells in 10 randomly chosen 1 X 1-mm fields excluding 0.4% trypan blue, and the quantitative release of creatine kinase into the medium after 6 h of exposure to TNFa (21) . The presence or absence of nucleosome laddering was taken as evidence for TNFa-induced apoptotic cell death (23 As an additional control experiment, we also examined changes in fluorescence brightness in the same cell, before and after treatment with TNF. For these studies, cells were loaded with fluo-3 and stimulated to contract as described above. Measurements of intracellular fluorescence brightness were then obtained for individual cells at baseline and 30 min after treatment with TNF (200 U/ml).
Third, to determine whether the TNFa-induced contractile dysfunction was the result of a defect in cross-bridge activation, the extent of cell shortening was examined under conditions which we have shown to produce tetanus in isolated feline cardiocytes (20) . The extent of cell shortening was recorded on videotape and stored for playback; cardiocyte resting length and length at peak shortening were measured by edge detection.
Electrophysiology. To determine whether the effects of TNFa might be secondary to alterations in the inward calcium current, we used the whole-cell patch-clamp technique to measure the current-voltage relationship in isolated cardiac myocytes (26). Freshly isolated single cardiac myocytes were studied in KHB buffer maintained at room temperature. The pipette resistance was 2-8 Mg when filled with the intracellular solution (mM): 150 K-aspartate, 5 NaCl, 10 Hepes, 1 MgCl2, and 5 EGTA and 0.1 CaC12. In the whole-cell configuration baseline measurements of whole cell current (protocol below) were obtained every minute for 5 min during perfusion with KHB using a gravity-driven multibarrel perfusion system. After establishing that the calcium current was stable, TNFa (200 U/ml) in KHB was applied to the myocytes (n = 12) via the perfusion system; measurements were obtained in the presence ofTNFa every 2 min for a total of 15-20 min. Four experiments were performed to delineate the immediate molecular basis for the TNFa-induced effect on cardiocyte contractility. To determine whether an increase in synthesis of nitric oxide was important in terms ofmediating the acute negative inotropic effects ofTNFa, as has been suggested recently for thin strips of myocardial tissue (27) , a series of three interrelated experiments were conducted. First, two different inhibitors of nitric oxide synthase were employed in order to attenuate the TNFa-induced contractile dysfunction in isolated cardiocytes. Briefly, freshly isolated cells were pretreated for 1 h with Nmethyl-L-arginine (range 10-1,000MgM) or NG-nitro-L-arginine (range 10-1,000 MM) (28, 29) before stimulation (30 min) with 200 U/ml TNFa; control cells were treated for an equivalent period of time with diluent. Second, we measured the oxidation of nitric oxide, whose halflife is on the order of seconds (30) , by determining nitrite levels in diluent and TNFa-treated cultures. Nitrite production was determined by diazotation and absorbance reading at 540 nm (31 ) . The sensitivity of this technique is 200 pmol/ml ( 31 ) . Briefly, cells were incubated in KHB buffer and treated with 200 U/ml TNFa for 30 min or 6 h. The cells were then centrifuged and the pellet measured for total cardiocyte protein using the bicinchoninic assay (32) . Cell-free aliquots (400 1l) of supernatant were mixed with an equal volume of 1% sulfanilamide-0.1% N-[ I-naphthyl] ethylenediamine dihydrochloride in 2% phosphoric acid (Greiss reagent) at room temperature for 10 min. All nitrite concentrations were determined relative to a standard curve, which was obtained using an aqueous solution of sodium nitrite as a standard; Three additional experiments were performed to delineate a possible molecular basis for the TNFa-induced effect on cardiocyte contractility. Inasmuch as previous reports have suggested that de novo protein synthesis (33) or arachidonic acid (34, 35) metabolism might be important in terms of mediating some ofthe effects ofTNFa, we measured cell motion after pretreating the cell cultures (2 X I05 cells/ml) for 1 h with 2 X l0-5 M cycloheximide ( 19) , 100 MM indomethacin (36) or for 1 or 5 h with 10-6 M hydrocortisone. For these studies, hydrocortisone and indomethacin were dissolved in ethyl alcohol; the final concentration of ethyl alcohol used was 0.01% and 0.1%, respectively, for the hydrocortisone and indomethacin studies. To be certain that the concentration of ethyl alcohol used in these studies would not affect cardiocyte contractility adversely, in preliminary control experiments we established that < 0.1% ethyl alcohol did not affect cardiocyte motion significantly. After treatment with cycloheximide, indomethacin, or hydrocortisone, cardiocyte cultures were treated with 200 U/ml of TNFa for 30 min and cardiocyte contractility was assessed as described above; control cultures were handled identically with the exception that they were treated with diluent only. Data were expressed in terms ofthe percent change in cardiocyte shortening compared with control values. Finally, to determine whether TGFf3 was capable of attenuating the TNFa-induced effects on cardiocyte contractile dysfunction, as has been suggested by a recent study in vivo (5), freshly isolated cells were treated for 1 or 5 h with TGF3 (range 1-100 ng/ml) and then treated with 200 U/ml TNFa for 30 min; control cells were treated with 100 ng/ml TGF,. Cell motion was then characterized as described above.
Materials
Recombinant human TNFa (Genzyme Corp., Cambridge, MA) was used throughout these studies; a rabbit polyclonal anti-human TNFa antibody was used to neutralize the effects ofTNFa (Genzyme Corp.). The source for the chemicals utilized in these experiments were as follows: tissue culture grade chemicals for buffer solutions, BSA, indomethacin, cycloheximide, sodium nitroprusside, N0-methyl-L-arginine, phenol, ethidium bromide, caffeine, and sulfanilamide-0. 1% 
Statistical analysis
Each value is expressed as a mean ± SE. Nonpaired t tests were used to evaluate mean differences in cardiocyte motion for cells treated with one or more inhibitors, either in the presence and absence of a single concentration of TNFa. Paired t tests were used to evaluate mean differences in the peak inward calcium current. One-way analysis of variance was used to evaluate differences in the peak extent of cardiocyte shortening in the presence of varying concentrations of TNFa. Twoway analysis of variance was used to evaluate differences between and within groups in peak developed LV pressure, peak LV dP/dT in the presence or absence of varying concentrations of TNFa, differences in the extent of cardiocyte shortening in the presence of varying concentrations of superfusate calcium, or differences in the current-voltage relationship in the presence and absence of TNFa. Where appropriate, post-hoc multiple comparison testing was performed (Dunnett's) to test for differences between control and experimental groups. Significant differences were said to exist at P < 0.05.
Results
Effects of TNFa on myocardialfunction Panels A and B of Fig. 1 show, respectively, the results of the studies wherein the percent change in peak developed LV systolic pressure or the percent change in peak LV dP/dT were examined after treatment with diluent or TNFa (10 and 50 U/s). As shown, there was no significant change in either the peak developed systolic pressure or the peak dP/dT pressure during infusion with diluent or the lower concentration of TNFa. In contrast, there was a significant decrease in both the peak developed pressure (P < 0.032) and the peak dP/dT(P < 0.002) after treatment with 50 U/s ofTNFa; post-hoc analysis of variance indicated that these changes were significantly (P < 0.05) different from control values by 20 min of treatment. Two-way analysis ofvariance showed that the values for peak developed LV pressure and peak dP/dT were signifi- However, relative to the curves for diluent and 10 U/s TNFa, the curve for 50 U/s of TNFa was shifted downward significantly (P < 0.04), suggesting a decrease in LV contractility. Cardiocyte contractility. Fig. 4 summarizes the studies wherein the extent of cardiocyte shortening was examined for cells treated with concentrations of TNFa ranging from 50 to 200 U/ml. As shown, there was an inverse relationship between the concentration of TNFa used and the extent of cardiocyte shortening. Analysis of variance indicated that these overall changes were significant statistically (P < 0.001 ); multiple comparison testing indicated there were significant differences from control for TNFa concentrations 2 100 U/ml. Table I shows that there was a similar significant (P < 0.001) decrease in the velocity of cardiocyte shortening as a function of increasing concentration of TNFa. The specificity of the TNFa-induced effects was confirmed in the studies wherein an anti-human TNFa antibody was used to neutralize the effects of TNFa. As shown in Fig. 4 Electrophysiology. To determine whether the above alterations in calcium homestasis were secondary to changes in the inward calcium current, we used the whole-cell patch-clamp technique to measure the current voltage relationship in isolated cardiac myocytes. Fig. 7 summarizes the results of the patch-clamp studies in isolated cardiac myocytes. Panel A shows the superimposed currents elicited in a cardiac myocyte in response to voltage steps to -20 (upper tracing), 0 (middle tracing), and + 20 mV under baseline conditions and after treatment with 200 U/ml TNFa for 15 min. As shown, the inward currents were virtually unchanged after treatment with TNFa. The current-voltage relationships for group data (n = 12 cells) are summarized in panel B. As shown, the overlap for the current-voltage relationship was considerable after treatment with 200 U/ml TNFa. Two-way analysis ofvariance indicated that the current voltage relationship for TNFatreated cells was not significantly different from that obtained under baseline conditions (P = 0.39); moreover, there was no significant difference in the magnitude (P = 0.54) of the peak inward calcium current after treatment with TNFa. Thus, treatment with TNFa did not to lead to significant differences in the current-voltage relationship or magnitude of the inward calcium current in isolated cardiac myocytes. This statement notwithstanding, it should be recognized that a potential limitation ofthe whole-cell patch-clamp technique is that electrolyte solutions contained within the patch electrode may exchange freely with the intracellular contents ofthe cell (37) . Thus, we cannot completely discount the possibility that, under the experimental conditions used herein, TNFa might have had a small second-messenger-mediated effect on ion flux that was not evident because of intracellular dilutional effects arising from the patch electrode.
Molecular basis for the effect of TNFa on cardiocyte contractility
To determine the molecular basis for the TNFa-induced effects on cardiocyte function, a series of five experiments were performed. Table II summarizes 400 600 confirm these findings in popula-TIME (ms) tions of cells, we examined fluo-3 (inE ems) brightness in the same cell (n = 15) before and after treatment with TNFa. This study showed that peak intracellular fluorescent brightness was -40% less for the same cell after treatment with TNFa ( 1,631 ± 126 vs. 647±64.4 U; P = 0.001 ); again baseline intracellular brightness was similar both before (229±36.7 U) and after treatment with TNFa (205.4±35.6; P = 0.66). Finally, in control experiments we observed that there was no significant difference (P = 0.19) in the peak intracellular fluorescent brightness in digitonin permeabilized cardiac myocytes either in the presence (n = 51 cells) or absence (n = 44 cells) of TNFa, thus suggesting that this cytokine did not interfere with the emission strength of the fluo-3 signal. Voltage (mV) Figure 7 . (Fig. 4 , Table I ) that also was fully reversible upon removing this cytokine from the superfusate. It is noteworthy that the effects of TNFa observed in isolated cardiac myocytes were not only qualitatively similar to those found in the intact heart, in that the cytokine-induced effects were concentration-and time-dependent in both preparations, but they were also quantitatively similar as well. Indeed, both the time to onset of the TNFa-induced negative inotropic effects (-15-20 min) and the concentration of TNFa necessary to produce the negative inotropic effects (-90-100 U/ml), were similar in the intact heart and the isolated cardiac myocyte. Third, the data suggest that the negative inotropic effects ofTNFa are the direct result ofalterations in intracellular calcium homeostasis. This conclusion is based upon the digital imaging microscopy studies wherein treatment with TNFa led to a striking decrease in peak intracellular fluorescence during the systolic contraction sequence (Fig. 6 ), as well as the myocyte tetanization studies which showed that the negative inotropic effects of TNFa were abolished by repetitively stimulating the cross-bridges in the presence of elevated levels of myoplasmic calcium (20) . Thus, under experimental conditions that restore depressed levels of intracellular calcium, one is able to overcome the negative inotropic effects of TNFa.
Although we cannot exclude subtle alterations in myofilament sensitivity as a potential mechanism for the negative inotropic effects of TNFa, the data summarized in Fig. 5 Fig. 5 , we observed that the magnitude of the difference in cardiocyte shortening remained constant between control and TNFa-treated cells, despite using a broad range of calcium concentrations. Finally, it should be emphasized that none ofthe effects ofTNFa on myocardial or cellular function could be attributed to a cytokine-induced decrease in cardiac myocyte viability, inasmuch as there was no evidence for necrosis or apoptosis (Fig. 3) in cardiocyte cultures treated with TNFa; moreover, all of the TNFa-induced effects were completely reversible with time.
Effects ofTNFa on myocardialfunction. In examining the general point ofview that TNFa adversely affects cardiovascularfunction, previous studies have shown that direct injections ofTNFa in experimental animals produce hypotension, metabolic acidosis, hemoconcentration, and death within minutes to hours, thus mimicking the hemodynamic response seen during endotoxin-induced septic shock (39-42). Moreover, injections of antibodies raised against TNFa have been shown to attenuate the hemodynamic collapse seen in endotoxin shock (43) . The importance of TNFa in the clinical setting has been suggested both by studies in which injection of endotoxin into humans resulted in elevations in TNFa and depressed LV ejection performance (8) , as well as studies wherein TNFa infusions in patients undergoing antitumor therapy resulted in profound systemic hypotension (10) (11) (12) .
In examining the more specific point of view that TNFa adversely affects myocardialfunction, previous studies employing rat neonatal myocyte preparations have shown that TNFa blunts the positive inotropic effect ofisoproterenol after 72 h of exposure, but did not adversely affect baseline contractile function of these juvenile cells (44) (45) (46) . In contrast, a very recent study in which thin strips of myocardial tissue (27) were exposed to graded concentrations ofTNFa showed an immediate (2-3 min) concentration-dependent decrease in myocardial contractility which was completely reversible upon removal of this cytokine. Finally, a series ofin vivo studies in dogs showed that a single infusion of TNFa resulted in abnormalities of systolic and diastolic function within the first 24 h of infusion (9, 14, 47) . Of note, the most recent of these in vivo canine studies reported a time-dependent negative inotropic effect that was similar to the one observed in the present study ( 14) . Thus, the cellular studies presented herein both confirm and expand upon previous in vivo and in vitro studies in myocardial tissue. While the precise reason(s) for the discrepant findings between the present study and the previous study in neonatal rat myocytes is not apparent (44) (45) (46) , it is likely that the disparity may relate, at least in part, to one or more of the well-described developmental differences between neonatal and adult myocyte preparations (48, 49) .
Mechanism(s) of TNFa-induced contractile dysfunction. With respect to the potential mechanism(s) for TNFa-induced contractile defects, a recent study in rat neonatal cells suggests that subacute (48 h) exposure to TNFa leads to a G proteinmediated defect in gl-adrenergic signal transduction (45) . However, as noted above, these results in juvenile cells are quite different from those obtained in adult cells, and it is unlikely that the rapidity ofthe TNFa-induced changes in baseline contractile function in the present study can be explained completely by the subacute changes in G protein-mediated signal transduction.
A second more recent study in thin strips of myocardial tissue provided indirect evidence in support of the point of view that TNFa-induced contractile dysfunction resulted from "enhanced activity ofa constitutive nitric oxide synthase in the myocardium" (27) . As shown, the results ofthe present study demonstrate that the TNFa-induced abnormalities in contractile function can be explainedby decreased levels of intracellular calcium during the systolic contraction sequence. While the exact molecular mechanism(s) for this abnormality in calcium homeostasis is not clear, three lines of evidence suggest that a change in the level of intracellular nitric oxide is unlikely to be responsible for the TNFa-induced abnormality in intracellular calcium homeostasis. In accordance with previous studies by Moncado and coworkers (29), we were unable to detect any evidence for a TNFa-induced increase in the level of constitutive nitric oxide, as measured by changes in the level ofsuperfusate nitrite, the immediate oxidative breakdown product of nitric oxide (29) , or significant changes in the level ofcardiocyte cGMP (Table III) , the intracellular signalling pathway utilized by nitric oxide (29) . Moreover, we were unable to attenuate the acute negative inotropic effects of TNFa with two different inhibitors of nitric oxide synthase, despite using a broad range ofconcentrations for each agent. Finally, under the experimental conditions used herein, we were unable to detect a potential role for arachidonic acid metabolites (34), or for de novo protein synthesis (33) in terms of mediating the contractile dysfunction induced by TNFa, nor a potential direct role for TGFf in protecting the cardiocyte against TNFa-mediated injury (5) .
With respect to the potential mechanism(s) responsible for the TNFa-induced alterations in calcium homeostasis, the electrophysiological data presented herein do not support a potential role for alterations in the voltage sensitive inward calcium current (Fig. 7) as a likely mechanism for the negative inotropic effects ofTNFa. Nonetheless, these negative data do at least serve the heuristic purpose offocusing future mechanistic studies on the effects of TNFa on sarcoplasmic reticular function. Indeed, given that the downward (diastolic) slopes of the calcium transients in control and the TNFa-treated cells appear to be different (Fig. 6) , it is quite possible that TNFa may in fact alter sarcoplasmic reticular function in the adult cardiac myocyte.
Conclusion. Given the well-recognized association between the elaboration of TNFa during sepsis and the hemodynamic collapse that has become the hallmark ofthis condition (40) , it was not surprising to find that TNFa exerted direct negative inotropic effects in the intact heart. This statement notwithstanding, the importance of the present study is twofold. First, the study provides straightforward and compelling evidence that TNFa exerts its effects directly at the level of the adult cardiac myocyte, and not necessarily indirectly by releasing soluble factor(s) from nonmyrocyte-cell types -residing witihin the myocardium. Second, this study provides direct evidence for a cellular mechanism for the TNFa-induced contractile dysfunction. That is, treatment with TNFa led to alterations in intracellular calcium homeostasis that could explain the TNFa-induced alterations in contractile function completely. While direct correlations between short-term effects in isolated cells and long-term effects in the heart in vivo are not appropriate, these data do provide potential clinical insights into several cardiac disease states wherein elevated TNFa levels have been reported, including acute viral myocarditis (2) , cardiac allograft rejection (3) , subacute myocardial infarction (4, 5) , and congestive heart failure (6, 7). Although it remains to be determined whether pro-inflammatory cytokines play a pathogenetic role in any ofthese conditions, the findings ofthis study would at least provide a potential cellular basis for the LV dysfunction that often occurs during the course ofthese pathophysiological conditions.
